Sarepta Elevidys Withdrawal Refusal

News

Sarepta shares rebound

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for its muscular gene therapy soothes immediate concerns about liquidity and the therapy's withdrawal from the market.

Fierce Pharma · 8d

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market

BioPharma Dive · 8d

5 questions on Sarepta, the FDA and a Duchenne gene therapy crisis

Hosted on MSN1mon

Sarepta downgraded as company suspends guidance after latest Elevidys death

Wall Street analysts were quick to downgrade Sarepta Therapeutics (NASDAQ:SRPT) on Monday as the company suspended its revenue guidance for 2025 following a second fatality linked to Elevidys, its ...

Reuters1mon

Sarepta shares crash as second patient dies after receiving its gene ...

Shares of Sarepta Therapeutics closed down as much as 42% to hit a nine-year low of $18.30 on Monday after a second death of a male teenage patient who had received its gene therapy, Elevidys ...

Yahoo Finance11mon

Sarepta reveals lower Elevidys sales, but points to ‘massive ...

Sarepta management is predicting a significant uptick in use in the near future. Up until June, Elevidys was only available to certain boys with Duchenne who were 4 or 5 years old, capping its ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results